Bivalirudin Versus Heparin: A Fight Far From Finished?: Efficacy, Safety, and Cost Remain Battlegrounds for the Treatment Of ST-Segment Elevation Myocardial Infarction.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  P & T : a peer-reviewed journal for formulary management

• Publication date

  2015-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 25798042PMCID PMC4357354
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.

  2015cited by this paper
• Choice of optimal anticoagulant to support primary PCI: out with the new, in with the old.

  2015cited by this paper
• Real-Time Decision Support to Guide Percutaneous Coronary Intervention Bleeding Avoidance Strategies Effectively Changes Practice Patterns

  2014cited by this paper
• Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).

  2014cited by this paper
• Bivalirudin started during emergency transport for primary PCI.

  2013cited by this paper
• Bivalirudin Therapy Is Associated With Improved Clinical and Economic Outcomes in ST-Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: Results From an Observational Database

  2012cited by this paper
• The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction.

  2011cited by this paper
• Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

  2011cited by this paper
• Economic Impact of Switching to Bivalirudin for a Primary Percutaneous Coronary Intervention in a US Hospital

  2010cited by this paper
• Bivalirudin during primary PCI in acute myocardial infarction.

  2008cited by this paper

• Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis

  2024cites this paper
• Efficacy of bivalirudin sequential dose therapy in patients with ST-segment elevation myocardial infarction undergoing emergency intervention during the perioperative period

  2018cites this paper
• A Study of 1,236 Patients Supporting the Use of Unfractionated Heparin With or Without Glycoprotein IIb/IIIa Inhibitors over Bivalirudin in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Changing Trend

  2017cites this paper
• New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?

  2016cites this paper
• The search for optimal anticoagulation therapy in ACS: The gap between clinical trials and current clinical guidelines

  2015cites this paper